AbbVie announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.

The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program including six Phase III studies of more than 2,300 GT1 patients in over 25 countries. The regimen was granted a Breakthrough Therapy designation by the FDA in May 2013, a status given to investigational treatments for serious or life-threatening conditions with preliminary clinical evidence demonstrating substantial improvement on at least one clinically significant endpoint compared to available therapy.

In May 2014, AbbVie submitted marketing authorization applications for regulatory approval in the European Union.

For more details, go to: http://abbvie.mediaroom.com/2014-06-13-U-S-FDA-Grants-Priority-Review-to-AbbVie-for-Investigational-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Genotype-1-Chronic-Hepatitis-C